argenx SEARGX +3.01%80 Pretax Margin % is 32.82% as of Mar. 2026. GuruFocus rates ARGX with a GF Score™ of 80/100 and a GF Value™ of $1,363.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, argenx SE ranks better than 91.31% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. argenx SE's Pre-Tax Income for the
three
months ended in Mar. 2026 was $426 Mil. argenx SE's Revenue for the
three
months ended in Mar. 2026 was $1,298 Mil. Therefore, argenx SE's pretax margin for the quarter that ended in Mar. 2026 was 32.82%.
The historical rank and industry rank for argenx SE's Pretax Margin % or its related term are showing as below:
ARGX'
s Pretax Margin % Range Over the Past 10 Years
Min: -1467.76 Med: -112.83 Max: 32.23
Current: 32.23
ARGX's Pretax Margin % is ranked better than 91.31% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs ARGX: 32.23
argenx SE (NAS:ARGX) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
argenx SE Pretax Margin % Related Terms
argenx SE Pretax Margin % Historical Data
* Premium members only.
The historical data trend for argenx SE's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARGX vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, argenx SE's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where argenx SE's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (ARGX) has a Pretax Margin % of 32.82% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #82 out of 944 companies in the Biotechnology industry, placing it in the top 8.7%.
Is argenx SE's Pretax Margin % too high?
argenx SE's current Pretax Margin % is 32.82%. Based on the distribution chart, argenx SE ranks #82 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #82 out of 944 companies for Pretax Margin %. This places argenx SE in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on argenx SE and its competitors. argenx SE's current Pretax Margin % is 32.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (ARGX) is currently considered Significantly Undervalued. The stock's GF Value™ is $1,363.68, compared to a current price of $912.46 — trading 33.1% below its estimated fair value. The current Pretax Margin % is 32.82%. argenx SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For argenx SE (ARGX), the current Pretax Margin % is 32.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (ARGX) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of $912.46 is trading 33.1% below its estimated GF Value™ of $1,363.68.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for ARGX:
Pretax Margin %: 32.82%
GF Value™: $1,363.68 vs. price of $912.46 (33.1% below fair value)
No single metric tells the full story. See the ARGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score
Get the complete analysis for ARGX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARGX has been successfully added to your 
